Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AnorMED Inc.
Vancouver, British Columbia, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
At the time of its acquisition by Genzyme in late 2006, AnorMED’s lead product candidate Mozobil was a late-stage therapy for hematopoietic stem cell transplantation and expected to launch commercially around 2008. The company also had programs targeting HIV and cardiac tissue repair but prioritized its validated hematology/oncology pipeline.
- Therapeutic areas
- Infectious DiseasesCardiovascularHematology
- Modalities
- Small molecules (notably chemokine receptor antagonists)
- Industry
- Biotech
02
Partnerships
No major disclosed partnerships prior to Genzyme's acquisition
Beyond the preview
Go deeper on AnorMED Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AnorMED Inc..